Actinium Pharmaceuticals (ATNM) Faces Investor Lawsuit: What to Know About the May 2025 Deadline

Are you an investor in Actinium Pharmaceuticals (ATNM)? Recent news indicates that the company is facing a securities class action lawsuit, and if you purchased ATNM securities between October 31, 2022, and August 2, 2024, you may be affected. Several law firms have announced the lawsuit, and there’s an important deadline of May 26 or 27, 2025, to take action. Understanding the details of this lawsuit, your rights as an investor, and the potential implications is crucial.

What is the Lawsuit About?

The class action lawsuit alleges that Actinium Pharmaceuticals made false and/or misleading statements and/or failed to disclose critical information to investors during the specified class period. The core of the issue revolves around the company’s Biologics License Application (BLA) for Iomab-B, a targeted radiotherapy drug intended to treat relapsed or refractory acute myeloid leukemia (AML).

The lawsuit claims that Actinium misled investors regarding the likelihood of FDA approval for Iomab-B. Specifically, the company is accused of:

Touting positive data from the Phase 3 Sierra trial related to Complete Remission (DCR) while downplaying the trial’s failure to achieve statistically significant or clinically meaningful Overall Survival (OS) data.
Misleading investors about the importance of the poor Overall Survival data, suggesting that the FDA had approved the trial design in such a way that the OS data would not hinder BLA approval.

The truth, according to the lawsuit, emerged on August 5, 2024, when Actinium announced that the FDA had determined that the Sierra trial data was insufficient to support a BLA filing for Iomab-B and that an additional clinical study would be required. This announcement caused Actinium’s stock price to plummet, resulting in significant losses for investors. On this news, the price of Actinium’s common stock fell $3.69, or approximately to 60%, to close at $2.48 on August 5, 2024.

What are the Legal Claims?

The various law firms filing these suits allege violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. In simpler terms, the claim is that Actinium Pharmaceuticals and its officers made materially false and misleading statements, or omitted material facts, which led to financial harm for investors.

What is the Class Period?

The class period for this lawsuit is defined as October 31, 2022, to August 2, 2024, inclusive. If you purchased Actinium Pharmaceuticals (ATNM) securities during this time, you are potentially a member of the class and may be entitled to compensation.

The May 2025 Deadline: What You Need to Know

A critical aspect of this lawsuit is the upcoming deadline to apply to be a lead plaintiff. The deadline is either May 26 or May 27, 2025, depending on the law firm.

What is a Lead Plaintiff?

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. They oversee the case, work with the attorneys, and make decisions that affect the entire class.

Why is the Deadline Important?

Filing a motion to become lead plaintiff is crucial for investors who wish to have a greater say in the direction of the lawsuit. While you can still participate in the class action without being a lead plaintiff, taking on this role allows you to actively protect your interests and the interests of other investors who suffered similar losses.

What Should You Do?

If you believe you have a valid claim, consider the following:

Contact a law firm: Several firms specializing in securities litigation have announced the Actinium Pharmaceuticals lawsuit. Contacting them will allow you to discuss your potential claim, understand your rights, and explore your options for participating in the case. Some of the firms include The Schall Law Firm, Levi & Korsinsky, Rosen Law Firm, Scott+Scott Attorneys at Law LLP, and Pomerantz LLP.
Gather documentation: Collect any documents related to your purchase and sale of ATNM securities during the class period. This includes brokerage statements, trade confirmations, and any other records that can help establish your losses.
Understand the role of lead plaintiff: If you are interested in becoming a lead plaintiff, discuss the responsibilities and potential benefits with the law firm you choose to work with.
Be aware of the deadline: Mark May 26 or 27, 2025, on your calendar as the deadline to file a motion to become lead plaintiff.

Actinium Pharmaceuticals: What Do Analysts Predict?

Despite the ongoing lawsuit, analysts’ opinions on Actinium Pharmaceuticals’ stock vary.

Ratings: As of April 2025, the consensus among analysts is “Strong Buy” or “Moderate Buy”. However, it’s important to note that these ratings may not fully reflect the impact of the lawsuit.
Price Targets: Analyst price targets for ATNM stock vary widely. The average 12-month price target ranges from $4.50 to $8.75, with some analysts projecting as high as $21. However, some sources predict lower values.
Financial Health: Actinium Pharmaceuticals’ revenue estimate for 2025 is $0. Actinium Pharmaceuticals, Inc.’s EPS last quarter was $-0.21 and revenues were $81K. Actinium Pharmaceuticals, Inc.’s latest EPS estimate is $-0.29.

It’s crucial to conduct thorough research and consult with a financial advisor before making any investment decisions, especially considering the current legal challenges faced by the company.

Participating in the Class Action: What to Expect

If you choose to participate in the class action lawsuit, here’s a general overview of what you can expect:

Filing a Claim: If the lawsuit is successful (either through a settlement or a court judgment), you will need to file a claim to receive compensation. The claim form will require you to provide details about your ATNM stock transactions and the losses you incurred.
Distribution of Funds: If the court approves a settlement or judgment, the funds will be distributed to eligible class members based on a formula that takes into account the number of shares you purchased and when you purchased them.
Legal Fees and Expenses: The attorneys representing the class will typically receive a portion of the settlement or judgment as payment for their fees and expenses. This amount will be determined by the court.

Final Thoughts

The investor lawsuit against Actinium Pharmaceuticals is a significant development that warrants careful attention from anyone who invested in ATNM securities between October 31, 2022, and August 2, 2024. By understanding the details of the lawsuit, your rights as an investor, and the upcoming deadlines, you can make informed decisions about how to protect your financial interests. Don’t hesitate to seek legal counsel and conduct thorough research to navigate this complex situation.